Search

Your search keyword '"Bedard, Philippe L"' showing total 1,155 results
Start Over Author "Bedard, Philippe L"
1,155 results on '"Bedard, Philippe L"'

2. A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer

Author

Hernando-Calvo, Alberto, Han, Ming, Ayodele, Olubukola, Wang, Ben X., Bruce, Jeffrey P., Abbas-Aghababazadeh, Farnoosh, Vila-Casadesús, Maria, Sanz-Garcia, Enrique, Yang, S.Y. Cindy, Berman, Hal K., Vivancos, Ana, Lam, Bernard, Lungu, Ilinca, Salawu, Abdulazeez, Stayner, Lee-Anne, Haibe-Kains, Benjamin, Bedard, Philippe L., Avery, Lisa, Razak, Albiruni R.A., Pugh, Trevor J., Spreafico, Anna, Siu, Lillian L., and Hansen, Aaron R.

Published
2024
Full Text
View/download PDF

4. Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab

Author

Hernando-Calvo, Alberto, Yang, S.Y. Cindy, Vila-Casadesús, Maria, Han, Ming, Liu, Zhihui Amy, Berman, A Hal K., Spreafico, Anna, Razak, Albiruni Abdul, Lheureux, Stephanie, Hansen, Aaron R., Lo Giacco, Deborah, Abbas-Aghababazadeh, Farnoosh, Matito, Judith, Haibe-Kains, Benjamin, Pugh, Trevor J., Bratman, Scott V., Aleshin, Alexey, Berche, Roger, Saavedra, Omar, Garralda, Elena, Elston, Sawako, Siu, Lillian L., Ohashi, Pamela S., Vivancos, Ana, and Bedard, Philippe L.

Published
2024
Full Text
View/download PDF

6. Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment

Author

Baginska, Joanna, Nau, Allison, Gomez Diaz, Ilana, Giobbie-Hurder, Anita, Weirather, Jason, Vergara, Juliana, Abrecht, Charlotte, Hallisey, Margaret, Dennis, Jenna, Severgnini, Mariano, Huezo, Julia, Marciello, Isabella, Rahma, Osama, Manos, Michael, Brohl, Andrew S., Bedard, Philippe L., Renouf, Daniel J., Sharon, Elad, Streicher, Howard, Ott, Patrick A., Buchbinder, Elizabeth I., and Hodi, F. Stephen

Published
2024
Full Text
View/download PDF

7. Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)

Author

Genta, Sofia, Lajkosz, Katherine, Yee, Noelle R., Spiliopoulou, Pavlina, Heirali, Alya, Hansen, Aaron R., Siu, Lillian L., Saibil, Sam, Stayner, Lee-Anne, Yanekina, Maryia, Sauder, Maxwell B., Keshavarzi, Sareh, Salawu, Abdulazeez, Vornicova, Olga, Butler, Marcus O., Bedard, Philippe L., Razak, Albiruni R. Abdul, Rottapel, Robert, Chruscinski, Andrzej, Coburn, Bryan, and Spreafico, Anna

Published
2023
Full Text
View/download PDF

9. Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: a cost-consequence analysis using linked administrative data

Author

Hernando-Calvo, Alberto, Nguyen, Paul, Bedard, Philippe L., Chan, Kelvin K.W., Saleh, Ramy R., Weymann, Deirdre, Yu, Celeste, Amir, Eitan, Regier, Dean A., Gyawali, Bishal, Kain, Danielle, Wilson, Brooke, Earle, Craig C., Mittmann, Nicole, Abdul Razak, Albiruni R., Isaranuwatchai, Wanrudee, Sabatini, Peter, Spreafico, Anna, Stockley, Tracy L., Pugh, Trevor J., Williams, Christine, Siu, Lillian L., and Hanna, Timothy P.

Published
2024
Full Text
View/download PDF

13. A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials

Author

Hernando-Calvo, Alberto, Vila-Casadesús, Maria, Bareche, Yacine, Gonzalez-Medina, Alberto, Abbas-Aghababazadeh, Farnoosh, Lo Giacco, Deborah, Martin, Agatha, Saavedra, Omar, Brana, Irene, Vieito, Maria, Fasani, Roberta, Stagg, John, Mancuso, Francesco, Haibe-Kains, Benjamin, Han, Ming, Berche, Roger, Pugh, Trevor J., Mirallas, Oriol, Jimenez, Jose, Gonzalez, Nadia Saoudi, Valverde, Claudia, Muñoz-Couselo, Eva, Suarez, Cristina, Diez, Marc, Élez, Elena, Capdevila, Jaume, Oaknin, Ana, Saura, Cristina, Macarulla, Teresa, Galceran, Joan Carles, Felip, Enriqueta, Dienstmann, Rodrigo, Bedard, Philippe L., Nuciforo, Paolo, Seoane, Joan, Tabernero, Josep, Garralda, Elena, and Vivancos, Ana

Published
2023
Full Text
View/download PDF

14. Symptom screening with Targeted Early Palliative care (STEP) versus usual care for patients with advanced cancer: a mixed methods study

Author

Zimmermann, Camilla, Pope, Ashley, Hannon, Breffni, Bedard, Philippe L., Rodin, Gary, Dhani, Neesha, Li, Madeline, Herx, Leonie, Krzyzanowska, Monika K., Howell, Doris, Knox, Jennifer J., Leighl, Natasha B., Sridhar, Srikala, Oza, Amit M., Lheureux, Stephanie, Booth, Christopher M., Liu, Geoffrey, Castro, Jacqueline Alcalde, Swami, Nadia, Sue-A-Quan, Rachel, Rydall, Anne, and Le, Lisa W.

Published
2023
Full Text
View/download PDF

15. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

Author

Lin, Nancy U, Borges, Virginia, Anders, Carey, Murthy, Rashmi K, Paplomata, Elisavet, Hamilton, Erika, Hurvitz, Sara, Loi, Sherene, Okines, Alicia, Abramson, Vandana, Bedard, Philippe L, Oliveira, Mafalda, Mueller, Volkmar, Zelnak, Amelia, DiGiovanna, Michael P, Bachelot, Thomas, Chien, A Jo, O’Regan, Ruth, Wardley, Andrew, Conlin, Alison, Cameron, David, Carey, Lisa, Curigliano, Giuseppe, Gelmon, Karen, Loibl, Sibylle, Mayor, JoAl, McGoldrick, Suzanne, An, Xuebei, and Winer, Eric P

Subjects
Clinical Trials and Supportive Activities, Cancer, Clinical Research, Neurosciences, Breast Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Breast Neoplasms, Capecitabine, Disease Progression, Double-Blind Method, Female, Humans, Middle Aged, Oxazoles, Pyridines, Quinazolines, Receptor, ErbB-2, Trastuzumab, Young Adult, Receptor, erbB-2, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeIn the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer with brain metastases (BMs) showed statistically significant improvement in progression-free survival (PFS) with tucatinib. We describe exploratory analyses of intracranial efficacy and survival in participants with BMs.Patients and methodsPatients were randomly assigned 2:1 to tucatinib or placebo, in combination with trastuzumab and capecitabine. All patients underwent baseline brain magnetic resonance imaging; those with BMs were classified as active or stable. Efficacy analyses were performed by applying RECIST 1.1 criteria to CNS target lesions by investigator assessment. CNS-PFS (intracranial progression or death) and overall survival (OS) were evaluated in all patients with BMs. Confirmed intracranial objective response rate (ORR-IC) was evaluated in patients with measurable intracranial disease.ResultsThere were 291 patients with BMs: 198 (48%) in the tucatinib arm and 93 (46%) in the control arm. The risk of intracranial progression or death was reduced by 68% in the tucatinib arm (hazard ratio [HR], 0.32; 95% CI, 0.22 to 0.48; P < .0001). Median CNS-PFS was 9.9 months in the tucatinib arm versus 4.2 months in the control arm. Risk of death was reduced by 42% in the tucatinib arm (OS HR, 0.58; 95% CI, 0.40 to 0.85; P = .005). Median OS was 18.1 versus 12.0 months. ORR-IC was higher in the tucatinib arm (47.3%; 95% CI, 33.7% to 61.2%) versus the control arm (20.0%; 95% CI, 5.7% to 43.7%; P = .03).ConclusionIn patients with HER2-positive breast cancer with BMs, the addition of tucatinib to trastuzumab and capecitabine doubled ORR-IC, reduced risk of intracranial progression or death by two thirds, and reduced risk of death by nearly half. To our knowledge, this is the first regimen to demonstrate improved antitumor activity against BMs in patients with HER2-positive breast cancer in a randomized, controlled trial.

Published
2020

17. Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial

Author

Veitch, Zachary W, Cescon, David W, Denny, Trisha, Yonemoto, Lisa-Maria, Fletcher, Graham, Brokx, Richard, Sampson, Peter, Li, Sze-Wan, Pugh, Trevor J, Bruce, Jeffrey, Bray, Mark R, Slamon, Dennis J, Mak, Tak W, Wainberg, Zev A, and Bedard, Philippe L

Subjects
Clinical Trials and Supportive Activities, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Antineoplastic Agents, Dose-Response Relationship, Drug, Female, Humans, Indazoles, Indoles, Male, Middle Aged, Neoplasms, Neutropenia, Protein Serine-Threonine Kinases, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundCFI-400945 is a first-in-class oral inhibitor of polo-like kinase 4 (PLK4) that regulates centriole duplication. Primary objectives of this first-in-human phase 1 trial were to establish the safety and tolerability of CFI-400945 in patients with advanced solid tumours. Secondary objectives included pharmacokinetics, pharmacodynamics, efficacy, and recommended phase 2 dose (RP2D).MethodsContinuous daily oral dosing of CFI-400945 was evaluated using a 3+3 design guided by incidence of dose-limiting toxicities (DLTs) in the first 28-day cycle. Safety was assessed by CTCAE v4.0. ORR and CBR were evaluated using RECIST v1.1.ResultsForty-three patients were treated in dose escalation from 3 to 96 mg/day, and 9 were treated in 64 mg dose expansion. After DLT occurred at 96 and 72 mg, 64 mg was established as the RP2D. Neutropenia was a common high-grade (19%) treatment-related adverse event at ≥ 64 mg. Half-life of CFI-400945 was 9 h, with Cmax achieved 2-4 h following dosing. One PR (45 cycles, ongoing) and two SD ≥ 6 months were observed (ORR = 2%; CBR = 6%).ConclusionsCFI-400945 is well tolerated at 64 mg with dose-dependent neutropenia. Favourable pharmacokinetic profiles were achieved with daily dosing. Response rates were low without biomarker pre-selection. Disease-specific and combination studies are ongoing.Trial registrationClinical Trials Registration Number - NCT01954316 (Oct 1st, 2013).

Published
2019

22. Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

Author

Hilton, John, Gelmon, Karen, Bedard, Philippe L., Tu, Dongsheng, Xu, Hong, Tinker, Anna V., Goodwin, Rachel, Laurie, Scott A., Jonker, Derek, Hansen, Aaron R., Veitch, Zachary W., Renouf, Daniel J., Hagerman, Linda, Lui, Hongbo, Chen, Bingshu, Kellar, Deb, Li, Irene, Lee, Sung-Eun, Kono, Takako, Cheng, Brian Y. C., Yap, Damian, Lai, Daniel, Beatty, Sean, Soong, John, Pritchard, Kathleen I., Soria-Bretones, Isabel, Chen, Eric, Feilotter, Harriet, Rushton, Moira, Seymour, Lesley, Aparicio, Samuel, and Cescon, David W.

Published
2022
Full Text
View/download PDF

23. Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction

Author

Voon, Pei Jye, Chen, Eric X., Chen, Helen X., Lockhart, Albert C., Sahebjam, Solmaz, Kelly, Karen, Vaishampayan, Ulka N., Subbiah, Vivek, Razak, Albiruni R., Renouf, Daniel J., Hotte, Sebastien J., Singh, Arti, Bedard, Philippe L., Hansen, Aaron R., Ivy, S. Percy, Wang, Lisa, Stayner, Lee-Anne, Siu, Lillian L., and Spreafico, Anna

Published
2022
Full Text
View/download PDF

25. A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

Author

Reynolds, Kerry Lynn, Bedard, Philippe L, Lee, Se-Hoon, Lin, Chia-Chi, Tabernero, Josep, Alsina, Maria, Cohen, Ezra, Baselga, José, Blumenschein, George, Graham, Donna M, Garrido-Laguna, Ignacio, Juric, Dejan, Sharma, Sunil, Salgia, Ravi, Seroutou, Abdelkader, Tian, Xianbin, Fernandez, Rose, Morozov, Alex, Sheng, Qing, Ramkumar, Thiruvamoor, Zubel, Angela, and Bang, Yung-Jue

Subjects
Breast Cancer, Clinical Research, Clinical Trials and Supportive Activities, Cancer, Rare Diseases, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Adult, Aged, Antineoplastic Agents, Immunological, Bayes Theorem, Breast Neoplasms, Carcinoma, Squamous Cell, Dose-Response Relationship, Drug, Esophageal Neoplasms, Female, Head and Neck Neoplasms, Humans, Male, Maximum Tolerated Dose, Middle Aged, Receptor, ErbB-2, Receptor, ErbB-3, Squamous Cell Carcinoma of Head and Neck, Stomach Neoplasms, Phase I, HER3, HER2, Monoclonal antibody, LJM716, Receptor, erbB-2, Receptor, erbB-3, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundHuman epidermal growth factor receptor 3 (HER3) is important in maintaining epidermal growth factor receptor-driven cancers and mediating resistance to targeted therapy. A phase I study of anti-HER3 monoclonal antibody LJM716 was conducted with the primary objective to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE), and dosing schedule. Secondary objectives were to characterize safety/tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity.MethodsThis open-label, dose-finding study comprised dose escalation, followed by expansion in patients with squamous cell carcinoma of the head and neck or esophagus, and HER2-overexpressing metastatic breast cancer or gastric cancer. During dose escalation, patients received LJM716 intravenous once weekly (QW) or every two weeks (Q2W), in 28-day cycles. An adaptive Bayesian logistic regression model was used to guide dose escalation and establish the RDE. Exploratory pharmacodynamic tumor studies evaluated modulation of HER3 signaling.ResultsPatients received LJM716 3-40 mg/kg QW and 20 mg/kg Q2W (54 patients; 36 patients at 40 mg/kg QW). No dose-limiting toxicities (DLTs) were reported during dose-escalation. One patient experienced two DLTs (diarrhea, hypokalemia [both grade 3]) in the expansion phase. The RDE was 40 mg/kg QW, providing drug levels above the preclinical minimum effective concentration. One patient with gastric cancer had an unconfirmed partial response; 17/54 patients had stable disease, two lasting >30 weeks. Down-modulation of phospho-HER3 was observed in paired tumor samples.ConclusionsLJM716 was well tolerated; the MTD was not reached, and the RDE was 40 mg/kg QW. Further development of LJM716 is ongoing.Trial registrationClinicaltrials.gov registry number NCT01598077 (registered on 4 May, 2012).

Published
2017

27. Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors

Author

Stutheit-Zhao, Eric Y., primary, Sanz-Garcia, Enrique, additional, Liu, Zhihui (Amy), additional, Wong, Derek, additional, Marsh, Kayla, additional, Abdul Razak, Albiruni R., additional, Spreafico, Anna, additional, Bedard, Philippe L., additional, Hansen, Aaron R., additional, Lheureux, Stephanie, additional, Torti, Dax, additional, Lam, Bernard, additional, Yang, Shih Yu Cindy, additional, Burgener, Justin, additional, Luo, Ping, additional, Zeng, Yong, additional, Cheng, Nicholas, additional, Awadalla, Philip, additional, Bratman, Scott V., additional, Ohashi, Pamela S., additional, Pugh, Trevor J., additional, and Siu, Lillian L., additional

Published
2024
Full Text
View/download PDF

28. A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy

Author

Fankhauser, Christian Daniel, Tran, Ben, Pedregal, Manuel, Ruiz-Morales, José Manuel, Gonzalez-Billalabeitia, Egon, Patrikidou, Anna, Amir, Eitan, Seidel, Christoph, Bokemeyer, Carsten, Hermanns, Thomas, Rumyantsev, Alexey, Tryakin, Alexey, Brito, Margarida, Fléchon, Aude, Kwan, Edmon M., Cheng, Tina, Castellano, Daniel, del Muro, Xavier Garcia, Hamid, Anis A., Ottaviano, Margaret, Palmieri, Giovanella, Kitson, Robert, Reid, Alison, Heng, Daniel Y.C., Bedard, Philippe L., Sweeney, Christopher J., and Connors, Jean M.

Published
2021
Full Text
View/download PDF

33. Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2–Activating Mutations: Results From the National Cancer Institute–Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B

Author

Bedard, Philippe L., Li, Shuli, Wisinski, Kari B., Yang, Eddy S., Limaye, Sewanti A., Mitchell, Edith P., Zwiebel, James A., Moscow, Jeffrey A., Gray, Robert J., Wang, Victoria, McShane, Lisa M., Rubinstein, Larry V., Patton, David R., Williams, P. Mickey, Hamilton, Stanley R., Conley, Barbara A., Arteaga, Carlos L., Harris, Lyndsay N., OʼDwyer, Peter J., Chen, Alice P., and Flaherty, Keith T.

Published
2022
Full Text
View/download PDF

34. Supplementary Figure 3 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry

Author

Sanz-Garcia, Enrique, primary, Brown, Samantha, primary, Lavery, Jessica A., primary, Weiss, Jessica, primary, Fuchs, Hannah E., primary, Newcomb, Ashley, primary, Postle, Asha, primary, Warner, Jeremy L., primary, LeNoue-Newton, Michele L., primary, Sweeney, Shawn M., primary, Pillai, Shirin, primary, Yu, Celeste, primary, Nichols, Chelsea, primary, Mastrogiacomo, Brooke, primary, Kundra, Ritika, primary, Schultz, Nikolaus, primary, Kehl, Kenneth L., primary, Riely, Gregory J., primary, Schrag, Deborah, primary, Govindarajan, Anand, primary, Panageas, Katherine S., primary, and Bedard, Philippe L., primary

Published
2024
Full Text
View/download PDF

35. Supplementary Figure 1 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry

Author

Sanz-Garcia, Enrique, primary, Brown, Samantha, primary, Lavery, Jessica A., primary, Weiss, Jessica, primary, Fuchs, Hannah E., primary, Newcomb, Ashley, primary, Postle, Asha, primary, Warner, Jeremy L., primary, LeNoue-Newton, Michele L., primary, Sweeney, Shawn M., primary, Pillai, Shirin, primary, Yu, Celeste, primary, Nichols, Chelsea, primary, Mastrogiacomo, Brooke, primary, Kundra, Ritika, primary, Schultz, Nikolaus, primary, Kehl, Kenneth L., primary, Riely, Gregory J., primary, Schrag, Deborah, primary, Govindarajan, Anand, primary, Panageas, Katherine S., primary, and Bedard, Philippe L., primary

Published
2024
Full Text
View/download PDF

36. Supplementary Tables from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry

Author

Sanz-Garcia, Enrique, primary, Brown, Samantha, primary, Lavery, Jessica A., primary, Weiss, Jessica, primary, Fuchs, Hannah E., primary, Newcomb, Ashley, primary, Postle, Asha, primary, Warner, Jeremy L., primary, LeNoue-Newton, Michele L., primary, Sweeney, Shawn M., primary, Pillai, Shirin, primary, Yu, Celeste, primary, Nichols, Chelsea, primary, Mastrogiacomo, Brooke, primary, Kundra, Ritika, primary, Schultz, Nikolaus, primary, Kehl, Kenneth L., primary, Riely, Gregory J., primary, Schrag, Deborah, primary, Govindarajan, Anand, primary, Panageas, Katherine S., primary, and Bedard, Philippe L., primary

Published
2024
Full Text
View/download PDF

37. Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry

Author

Sanz-Garcia, Enrique, primary, Brown, Samantha, additional, Lavery, Jessica A., additional, Weiss, Jessica, additional, Fuchs, Hannah E., additional, Newcomb, Ashley, additional, Postle, Asha, additional, Warner, Jeremy L., additional, LeNoue-Newton, Michele L., additional, Sweeney, Shawn M., additional, Pillai, Shirin, additional, Yu, Celeste, additional, Nichols, Chelsea, additional, Mastrogiacomo, Brooke, additional, Kundra, Ritika, additional, Schultz, Nikolaus, additional, Kehl, Kenneth L., additional, Riely, Gregory J., additional, Schrag, Deborah, additional, Govindarajan, Anand, additional, Panageas, Katherine S., additional, and Bedard, Philippe L., additional

Published
2024
Full Text
View/download PDF

38. Supplementary Figure 2 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry

Author

Sanz-Garcia, Enrique, primary, Brown, Samantha, primary, Lavery, Jessica A., primary, Weiss, Jessica, primary, Fuchs, Hannah E., primary, Newcomb, Ashley, primary, Postle, Asha, primary, Warner, Jeremy L., primary, LeNoue-Newton, Michele L., primary, Sweeney, Shawn M., primary, Pillai, Shirin, primary, Yu, Celeste, primary, Nichols, Chelsea, primary, Mastrogiacomo, Brooke, primary, Kundra, Ritika, primary, Schultz, Nikolaus, primary, Kehl, Kenneth L., primary, Riely, Gregory J., primary, Schrag, Deborah, primary, Govindarajan, Anand, primary, Panageas, Katherine S., primary, and Bedard, Philippe L., primary

Published
2024
Full Text
View/download PDF

39. Data from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry

Author

Sanz-Garcia, Enrique, primary, Brown, Samantha, primary, Lavery, Jessica A., primary, Weiss, Jessica, primary, Fuchs, Hannah E., primary, Newcomb, Ashley, primary, Postle, Asha, primary, Warner, Jeremy L., primary, LeNoue-Newton, Michele L., primary, Sweeney, Shawn M., primary, Pillai, Shirin, primary, Yu, Celeste, primary, Nichols, Chelsea, primary, Mastrogiacomo, Brooke, primary, Kundra, Ritika, primary, Schultz, Nikolaus, primary, Kehl, Kenneth L., primary, Riely, Gregory J., primary, Schrag, Deborah, primary, Govindarajan, Anand, primary, Panageas, Katherine S., primary, and Bedard, Philippe L., primary

Published
2024
Full Text
View/download PDF

40. TABLE 4 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry

Author

Sanz-Garcia, Enrique, primary, Brown, Samantha, primary, Lavery, Jessica A., primary, Weiss, Jessica, primary, Fuchs, Hannah E., primary, Newcomb, Ashley, primary, Postle, Asha, primary, Warner, Jeremy L., primary, LeNoue-Newton, Michele L., primary, Sweeney, Shawn M., primary, Pillai, Shirin, primary, Yu, Celeste, primary, Nichols, Chelsea, primary, Mastrogiacomo, Brooke, primary, Kundra, Ritika, primary, Schultz, Nikolaus, primary, Kehl, Kenneth L., primary, Riely, Gregory J., primary, Schrag, Deborah, primary, Govindarajan, Anand, primary, Panageas, Katherine S., primary, and Bedard, Philippe L., primary

Published
2024
Full Text
View/download PDF

41. FIGURE 1 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry

Author

Sanz-Garcia, Enrique, primary, Brown, Samantha, primary, Lavery, Jessica A., primary, Weiss, Jessica, primary, Fuchs, Hannah E., primary, Newcomb, Ashley, primary, Postle, Asha, primary, Warner, Jeremy L., primary, LeNoue-Newton, Michele L., primary, Sweeney, Shawn M., primary, Pillai, Shirin, primary, Yu, Celeste, primary, Nichols, Chelsea, primary, Mastrogiacomo, Brooke, primary, Kundra, Ritika, primary, Schultz, Nikolaus, primary, Kehl, Kenneth L., primary, Riely, Gregory J., primary, Schrag, Deborah, primary, Govindarajan, Anand, primary, Panageas, Katherine S., primary, and Bedard, Philippe L., primary

Published
2024
Full Text
View/download PDF

42. TABLE 3 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry

Author

Sanz-Garcia, Enrique, primary, Brown, Samantha, primary, Lavery, Jessica A., primary, Weiss, Jessica, primary, Fuchs, Hannah E., primary, Newcomb, Ashley, primary, Postle, Asha, primary, Warner, Jeremy L., primary, LeNoue-Newton, Michele L., primary, Sweeney, Shawn M., primary, Pillai, Shirin, primary, Yu, Celeste, primary, Nichols, Chelsea, primary, Mastrogiacomo, Brooke, primary, Kundra, Ritika, primary, Schultz, Nikolaus, primary, Kehl, Kenneth L., primary, Riely, Gregory J., primary, Schrag, Deborah, primary, Govindarajan, Anand, primary, Panageas, Katherine S., primary, and Bedard, Philippe L., primary

Published
2024
Full Text
View/download PDF

43. FIGURE 2 from Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry

Author

Sanz-Garcia, Enrique, primary, Brown, Samantha, primary, Lavery, Jessica A., primary, Weiss, Jessica, primary, Fuchs, Hannah E., primary, Newcomb, Ashley, primary, Postle, Asha, primary, Warner, Jeremy L., primary, LeNoue-Newton, Michele L., primary, Sweeney, Shawn M., primary, Pillai, Shirin, primary, Yu, Celeste, primary, Nichols, Chelsea, primary, Mastrogiacomo, Brooke, primary, Kundra, Ritika, primary, Schultz, Nikolaus, primary, Kehl, Kenneth L., primary, Riely, Gregory J., primary, Schrag, Deborah, primary, Govindarajan, Anand, primary, Panageas, Katherine S., primary, and Bedard, Philippe L., primary

Published
2024
Full Text
View/download PDF

45. Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients With Mixed Solid Tumors (GO30103)

Author

Garralda, Elena, primary, Oh, Do Youn, additional, Italiano, Antoine, additional, Bedard, Philippe L., additional, Delord, Jean‐Pierre, additional, Calvo, Emiliano, additional, LoRusso, Patricia, additional, Wainberg, Zev, additional, Cervantes, Andres, additional, Rodriguez‐Vida, Alejo, additional, Shemesh, Colby S., additional, Sane, Rucha, additional, Mendus, Diana, additional, Ding, Hao, additional, Hendricks, Robert, additional, Meng, Ray, additional, Cho, Byoung Chul, additional, Kim, Tae Won, additional, and Wu, Benjamin, additional

Published
2023
Full Text
View/download PDF

46. Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity

Author

Cindy Yang, S. Y., Lien, Scott C., Wang, Ben X., Clouthier, Derek L., Hanna, Youstina, Cirlan, Iulia, Zhu, Kelsey, Bruce, Jeffrey P., El Ghamrasni, Samah, Iafolla, Marco A. J., Oliva, Marc, Hansen, Aaron R., Spreafico, Anna, Bedard, Philippe L., Lheureux, Stephanie, Razak, Albiruni, Speers, Vanessa, Berman, Hal K., Aleshin, Alexey, Haibe-Kains, Benjamin, Brooks, David G., McGaha, Tracy L., Butler, Marcus O., Bratman, Scott V., Ohashi, Pamela S., Siu, Lillian L., and Pugh, Trevor J.

Published
2021
Full Text
View/download PDF

48. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab

Author

Bratman, Scott V., Yang, S. Y. Cindy, Iafolla, Marco A. J., Liu, Zhihui, Hansen, Aaron R., Bedard, Philippe L., Lheureux, Stephanie, Spreafico, Anna, Razak, Albiruni Abdul, Shchegrova, Svetlana, Louie, Maggie, Billings, Paul, Zimmermann, Bernhard, Sethi, Himanshu, Aleshin, Alexey, Torti, Dax, Marsh, Kayla, Eagles, Jenna, Cirlan, Iulia, Hanna, Youstina, Clouthier, Derek L., Lien, Scott C., Ohashi, Pamela S., Xu, Wei, Siu, Lillian L., and Pugh, Trevor J.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results